Immunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapy

In some cancers, patients responding to immune checkpoint inhibitors (ICI) usually harbor tumors with a higher tumor mutational burden and increased lymphocyte infiltration targeting mutation-derived neoantigens (neoAgs). In the NASIR-HCC trial, patients with hepatocellular carcinoma (HCC) received...

Descripció completa

Dades bibliogràfiques

Autors principals:	Belén Aparicio, Leyre Silva, Marta Ruiz, Diana Llópiz, David Repáraz, Patrick Theunissen, Ibon Tamayo, Josune Egea, Ana Igea, Cristian Smerdou, Maria Peñas, Cristina Perpiñá, Ana Matilla, María Varela, Maria Reig, Manuel de la Torre-Alaez, Josepmaria Argemí, Bruno Sangro, Sandra Hervás-Stubbs, Pablo Sarobe
Format:	Artigo
Idioma:	Inglês
Publicat:	Taylor & Francis Group 2026-12-01
Col·lecció:	OncoImmunology
Matèries:	Hepatocellular carcinoma neoantigens immunotherapy polyepitopic vaccines HLA transgenic mice
Accés en línia:	https://www.tandfonline.com/doi/10.1080/2162402X.2026.2645280
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!